Raxibacumab for inhalational anthrax after mass exposure
Part of Infections clinical trials.
This study is for people who have symptoms of inhalational anthrax after a mass exposure. It tests a medicine called raxibacumab to see if it helps and is safe. Anyone who receives this medicine as part of their care can join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have symptoms of inhalational anthrax from a mass exposure to anthrax bacteria.
- You have received or will receive raxibacumab from the national stockpile as part of your care.
- You are willing to follow the study procedures and give written consent (or a legal representative can consent for you).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study observes people in the US who have been diagnosed with systemic anthrax and treated with a medication called raxibacumab, which was given from a national emergency supply. The goal is to learn more about how this treatment works in real-world cases.
This study tests whether a medicine called Raphamin can safely and effectively treat acute bronchitis (a chest infection with cough) in adults. Raphamin may help reduce cough and breathing problems in the early stages of this condition.
This study tests a treatment called AIGIV (sometimes sold as Anthrasil) for people who get anthrax by breathing in the germs. The treatment is made from human antibodies that fight the anthrax toxin, and the study checks if it is safe and helps patients recover.
This trial tests an inhaled medication for adults with bronchiectasis, a lung condition that causes chronic cough and mucus. The goal is to see if the drug is safe and helpful in reducing symptoms and infections.
This study looks at patients who have been diagnosed with or are suspected to have systemic anthrax and are being treated with the medicine AIGIV. It aims to understand how well the treatment works and whether it is safe. The results may help improve care for people with this serious infection.
This trial tests a new medicine called Raphamin for treating sudden sinus infection (acute rhinosinusitis) in adults. It compares the medicine to a placebo to see if it can reduce symptoms like facial pain and pressure when started within the first 2 days of illness.
Hear when a new Infections, Bacterial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.